2015 has proven to be a bustling year so far for the Isomark team.
We have made strides with our second-generation
device development, continued to fill our current investment
round, applied for multiple grant opportunities, and launched a new,
multi-center clinical study.
In this newsletter we focus on our newly launched study, the addition
of a new medical advisor, and update you on recent developments with
Joe Kremer, CEO
A few times each year we will update you on our
progress. In between newsletters, please visit our website, www.isomark.com, for the most up-to-date
Research to Florida
allowing for increased study.
subjects enrolling at the University of Wisconsin Hospital and
Clinics, Isomark has launched a multi-center clinical trial at two
sites in Florida.
Both the University of Florida - Gainesville and Jacksonville have a
large patient population and a strong focus on surgery and trauma
Recently, the University of Florida - Gainesville was awarded a
$12 million, five-year grant from the NIH to establish a Sepsis
and Critical Illness Research Center. The center will study
long-term outcomes in patients treated for sepsis in the surgical and
trauma ICUs at UF Health Shands Hospital,
with the goal of developing clinical solutions for sepsis as well as
illnesses that stem from it and their enduring, dismal effects.
Welcomes Dr. Maki
of the infection prevention field.
Isomark is pleased to announce the
addition of Dr. Dennis Maki as a new medical advisor. Dr. Maki
is currently the Ovid O. Meyer Professor of Medicine in the Divisions
of Infectious Diseases and Pulmonary-Critical Care Medicine at the
University of Wisconsin School of Medicine and Public Health,
attending physician in the UWHC Center for Trauma and Life Support
and eICU, and former Head of the Division of
Infectious Diseases from 1979-2007.
Dr. Maki's research has focused on the prevention and management of
hospital-acquired and life-threatening infections. Through his
career, Dr. Maki has published more than 250 original papers and
700 abstracts of research presented at scientific meetings, both
national and international. On top of that, Dr. Maki's
publications have been cited by other researchers more than 16,000
times. He has received numerous awards, certifications, and has
served on multiple advisory boards, including the CDC, NIH, and HHS.
Isomark's laser spectroscopy team has adapted a carbon
isotopic spectrometer, one originally developed for a Mars mission,
to our needs and are continuing to make iterative steps at reducing
size and cost. Isomark and its partners have developed a foam
model (right) of the new Canary™.
As Isomark continues to work with partners to develop
a smaller and less expensive Canary, our firmware designer has been
diligently working to create an easy-to-use and intuitive graphical
user interface (GUI). The GUI will serve as a means of
communicating with and controlling the device.
Much of the device development is funded by a $1.7 million NIH SBIR
Isomark's patented non-invasive breath technology may allow for the
early detection of infection.
technology is under development and not available for use. To
stay up to date, be sure to watch our website and follow us online.